Meeting
2019 ASCO Annual Meeting
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
Authors
Cara Amanda Mathews
Women & Infants Hospital, Providence, RI
Cara Amanda Mathews , Kathleen N. Moore , Nicoletta Colombo , Giovanni Scambia , Byoung-Gie Kim , Ana Oaknin , Michael Friedlander , Alla Sergeevna Lisyanskaya , Anne Floquet , Alexandra Leary , Gabe S. Sonke , Charlie Gourley , Susana N. Banerjee , Amit M. Oza , Antonio González-Martín , Carol Aghajanian , William Hampton Bradley , Elizabeth S. Lowe , Ralph Bloomfield , Paul Disilvestro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01844986
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5541)
DOI
10.1200/JCO.2019.37.15_suppl.5541
Abstract #
5541
Poster Bd #
364
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
First Author: Sana Intidhar Labidi-Galy
Poster
2020 ASCO Virtual Scientific Program
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
First Author: Domenica Lorusso
Poster
2019 ASCO Annual Meeting
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
First Author: Michael Friedlander
Poster
2019 ASCO Annual Meeting
Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.
First Author: Nicoletta Colombo